Ranexa
OVERDOSE
No cases of intentional or accidental overdose with ranolazine have been reported. In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop. Because the QTc interval increases with ranolazine plasma concentration, continuous ECG monitoring may be warranted in the event of overdose. If required, general supportive measures should be initiated.
Since ranolazine is about 62% bound to plasma proteins, complete clearance of ranolazine by hemodialysis is not likely.
CONTRAINDICATIONS
Ranexa is contraindicated in patients:
- With pre-existing QT prolongation
- With hepatic impairment (Child-Pugh Classes A [mild], B [moderate] or C [severe]) (see CLINICAL PHARMACOLOGY, Hepatic Insufficiency, and Electrocardiographic Effects)
- On QT-prolonging drugs
- On potent and moderately potent CYP3A inhibitors, including diltiazem
Generic Name: Ranolazine
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Herbal First Aid
Herbal medicine is ancient, but only in recent years have many people started to take notice of its all natural healing powers. See more WebMD Videos »
Ranexa
Health Resources
Slideshows
2008 Election & Health Care on WebMD. Get Informed.
Updated & New
RxList does not provide medical advice, diagnosis or treatment.